Core Viewpoint - Meis Health (02415) announced that its subsidiary, Shanghai Meis Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for patients with acute and intercritical gout, with a project value of approximately RMB 21 million [1] Group 1 - The project aims to systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment through a combination of prospective and retrospective observational studies [1] - The company leverages over a decade of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies [1] - The digital solutions provided by the company aim to empower the healthcare ecosystem and improve the quality of medical services [1]
梅斯健康子公司中标中国某药企“痛风智管计划”大型真实世界研究项目